Skip to main content
Clinical Trials/NCT02612675
NCT02612675
Completed
Not Applicable

Plasma Glucose and Insulin Response to Two Oral Nutrition Supplements in Persons With Type 2 Diabetes Mellitus

Société des Produits Nestlé (SPN)1 site in 1 country13 target enrollmentJanuary 2013
ConditionsDiabetes

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Diabetes
Sponsor
Société des Produits Nestlé (SPN)
Enrollment
13
Locations
1
Primary Endpoint
Area under the blood glucose curve (AUC 0-240)
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

This will be a randomized, cross-over study of two oral nutrition supplements in individuals with Type 2 Diabetes.

Registry
clinicaltrials.gov
Start Date
January 2013
End Date
February 2013
Last Updated
10 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
Société des Produits Nestlé (SPN)
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age 20-75 yrs
  • Type 2 diabetes controlled with diet or diet and oral agent, with the exception of sulfonylureas such as glimepiride (Amaryl), glipizide (Glucotrol/Glucotrol XL) and glyburide (DiaBeta, Micronase, Glynase Prestabs); meglitinides such as reaglinide (Prandin) and nateglinide (Starlix); and alpha-glucosidase inhibitors such as acarbose (Precose) and miglitol (Glyset)
  • Hemoglobin A1C less than 9.0%
  • Fasting blood glucose less than 180 mg

Exclusion Criteria

  • Allergy to milk protein or any other component of the formula

Outcomes

Primary Outcomes

Area under the blood glucose curve (AUC 0-240)

Time Frame: Baseline, 10, 20, 30, 60, 90, 120, 150, 180, 210 and 240 minutes

Study Sites (1)

Loading locations...

Similar Trials